Loading...

Global X S&P Biotech ETF

CURE.AX•ASX
Financial Services
Asset Management - Global
A$45.17
A$-0.08(-0.18%)

Global X S&P Biotech ETF (CURE.AX) Stock Overview

Explore Global X S&P Biotech ETF’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 72.8/100

Key Financials

Market Cap29.6M
P/E RatioN/A
EPS (TTM)N/A
ROE0.00%
Fundamental Analysis

AI Price Forecasts

1 Week$43.24
1 Month$43.10
3 Months$45.72
1 Year Target$59.02

CURE.AX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Global X S&P Biotech ETF (CURE.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.04, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $59.02.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 29.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;